FILE:AGN/AGN-8K-20100907082706.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
 
 
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
 
 
On September 1, 2010, Allergan, Inc. (the "Company") announced that it reached a resolution (the "Settlement") with the United States Department of Justice regarding the previously reported government investigation into the Company's past U.S. sales and marketing practices relating to certain therapeutic uses of . For further information regarding the Settlement and related matters, see the Company's Current Report on Form 8-K filed on September 1, 2010. Subsequently, on September 3, 2010, a stockholder's derivative action was filed in the Delaware Chancery Court against the Company's Board of Directors (the "Board") and nominally, against the Company, alleging breaches of fiduciary duties by the Board and seeking to shift the costs of the Settlement, together with other costs and expenses, to the Board. The Company is investigating the action and expects to contest it vigorously.
Botox
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 


